Assembly Bio raises $107.4M net in equity offering of 3.9M shares at $26.50

Filed May 26, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  Completed underwritten offering of 3,358,602 common shares at $26.50 per share plus 415,000 pre-funded warrants at $26.499, raising $107.4M net after fees. Underwriters exercised full overallotment option for 566,040 additional shares.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• medium

  Offering included participation from Gilead Sciences (existing collaboration partner), Farallon Capital, Commodore Capital, Columbia Threadneedle, and other healthcare-focused institutional investors.

  Exhibit 99.1 verify on EDGAR →
• medium

  Net proceeds will fund clinical development of pipeline candidates targeting viral and liver diseases and general corporate purposes. No specific allocation or program milestones disclosed.

  Exhibit 99.1 verify on EDGAR →